Arcus Biosciences
RCUS
RCUS
183 hedge funds and large institutions have $811M invested in Arcus Biosciences in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 85 increasing their positions, 49 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
183
Holders Change
-3
Holders Change %
-1.61%
% of All Funds
2.45%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
26
Increased
85
Reduced
49
Closed
26
Calls
$26.4M
Puts
$1.52M
Net Calls
+$24.9M
Net Calls Change
+$24.9M
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.2M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$9.18M |
| 3 |
Morgan Stanley
New York
|
+$5.56M |
| 4 |
BlackRock
New York
|
+$4.81M |
| 5 |
Jane Street
New York
|
+$3.07M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.3M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$9.18M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$5.01M |
| 4 |
Millennium Management
New York
|
-$3.37M |
| 5 |
DC
Decheng Capital
Menlo Park,
California
|
-$3.29M |
